BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» SHAPE-shifter Tetralogic: MDS phase II shuts down, promise for CTCL HDAC?
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
SHAPE-shifter Tetralogic: MDS phase II shuts down, promise for CTCL HDAC?
Jan. 8, 2016
By
Randy Osborne
No Comments
Hopes that phase II data could "re-ignite the investment case" for Tetralogic Pharmaceuticals Corp. flamed out and the shares (NASDAQ:TLOG) plunged 76.1 percent, or $1.29, ending at 41 cents, as the firm offered mixed results from a pair of trials.
BioWorld